{
  "id": 7101194,
  "title": "Jim Cramer Weighs Amgen (AMGN) After Novartis Trial Failure",
  "url": "https://urgent.news/2026/09/12/jim-cramer-weighs-amgen-amgn-after-novartis-trial-failure",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-12T10:48:13.000Z",
  "source": {
    "name": "Yahoo Finance",
    "slug": "yahoo-finance",
    "url": "https://finance.yahoo.com/markets/stocks/articles/jim-cramer-weighs-amgen-amgn-104813723.html"
  },
  "original_language": "en",
  "account": "On September 8, Jim Cramer highlighted Amgen Inc. (NASDAQ:AMGN) during his Mad Money show, suggesting the stock may have limited downside following a 44-point decline. The downturn came after Novartis' cardiovascular trial failure, which could lead to the removal of Amgen's similar olpasiran drug from its portfolio. Amgen's olpasiran is designed to reduce lipoprotein(a), a genetic factor associated with cardiovascular disease risk. The drug's Phase 3 trial, OCEAN(a)-Outcomes, is still ongoing, with results expected in 2027 or 2028. Amgen's Repatha, a cholesterol-lowering drug, showed a 20% reduction in death risk in a recent trial, while its sales grew 37% year-over-year to $953 million in Q2. Despite the setback, Cramer believes the stock may not experience a significant further drop due to Amgen's existing products and ongoing olpasiran studies. The company's total revenue increased 10% to $10.1 billion, and management maintained its revenue guidance for 2026.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}